MCK vs. COR, CAH, BDX, ZTS, GILD, HCA, BMY, DXCM, EW, and GSK
Should you be buying McKesson stock or one of its competitors? The main competitors of McKesson include Cencora (COR), Cardinal Health (CAH), Becton, Dickinson and Company (BDX), Zoetis (ZTS), Gilead Sciences (GILD), HCA Healthcare (HCA), Bristol-Myers Squibb (BMY), DexCom (DXCM), Edwards Lifesciences (EW), and GSK (GSK). These companies are all part of the "medical" sector.
Cencora (NYSE:COR) and McKesson (NYSE:MCK) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, community ranking, media sentiment, valuation and institutional ownership.
Cencora presently has a consensus target price of $233.90, suggesting a potential upside of 3.16%. McKesson has a consensus target price of $536.71, suggesting a potential downside of 1.44%. Given McKesson's higher probable upside, equities analysts clearly believe Cencora is more favorable than McKesson.
McKesson received 208 more outperform votes than Cencora when rated by MarketBeat users. Likewise, 74.09% of users gave McKesson an outperform vote while only 65.12% of users gave Cencora an outperform vote.
In the previous week, Cencora had 11 more articles in the media than McKesson. MarketBeat recorded 37 mentions for Cencora and 26 mentions for McKesson. Cencora's average media sentiment score of 0.47 beat McKesson's score of 0.33 indicating that McKesson is being referred to more favorably in the news media.
Cencora has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500. Comparatively, McKesson has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500.
McKesson has a net margin of 0.99% compared to McKesson's net margin of 0.67%. McKesson's return on equity of 268.67% beat Cencora's return on equity.
97.5% of Cencora shares are owned by institutional investors. Comparatively, 85.1% of McKesson shares are owned by institutional investors. 15.8% of Cencora shares are owned by insiders. Comparatively, 0.2% of McKesson shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Cencora pays an annual dividend of $2.04 per share and has a dividend yield of 0.9%. McKesson pays an annual dividend of $2.48 per share and has a dividend yield of 0.5%. Cencora pays out 22.3% of its earnings in the form of a dividend. McKesson pays out 11.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Cencora has raised its dividend for 1 consecutive years and McKesson has raised its dividend for 16 consecutive years.
McKesson has higher revenue and earnings than Cencora. McKesson is trading at a lower price-to-earnings ratio than Cencora, indicating that it is currently the more affordable of the two stocks.
Summary
McKesson beats Cencora on 13 of the 21 factors compared between the two stocks.
Get McKesson News Delivered to You Automatically
Sign up to receive the latest news and ratings for MCK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MCK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
McKesson Competitors List
Related Companies and Tools
